PDL1/CD155/TCR Activator/CHO
CBP74127

Contents

PDL1/CD155/TCR Activator/CHO
CBP74127

I. Background

The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.

CD155, or poliovirus receptor (PVR), has recently emerged as a pro-tumo rigenic antigen, overexpressed on GBM and contributing to increased GB M migration and aggressiveness. CD155 has also been established as an i mmunomodulatory receptor, able to both activate NK cells through intera ctions with CD226 (DNAM-1) and CD96 and inhibit them through intera ction with TIGIT.

Tel/QQ: 4008-750-250
Email: sales@cobioer.com
www.cobioer.com No.222 Changhong Road,Yuhua,Nanjing,Jiangsu

II. Introduction

Expressed gene: PDL1、CD155、TCR Activator

Stability: 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Freeze Medium: 90% FBS+10% DMSO

Culture Medium: F12K+10%FBS+600ug/ml hygromycin+2ug/ml puromycin+5ug/ml blasticidin

Mycoplasma Testing: Negative

Storage: Liquid nitrogen

Application(s): Functional(Report Gene) Assay

III. Representative Data



Figure 1. Dose Response of Blocking Antibodies in PD-1/TIGIT Dual Effector Reporter Cells (Clone 7) With PD-L1&CD155/ TCR Activator - CHO Cells.

Tel/QQ: 4008-750-250
Email: sales@cobioer.com
www.cobioer.com No.222 Changhong Road,Yuhua,Nanjing,Jiangsu